Paraproteinemia and Neuropathy
This program is worth up to 1.0 CME credits.
This course examines the importance of paraproteinemia from a neurologist's perspective. Learners will recognize the importance of screening for monoclonal gammopathies in patients with neuropathy, and what diagnostic tests are most useful. The course will also provide a practical approach to identifying potentially treatable or dangerous conditions associated with paraproteinemia.
Up to 1.0 CME credit
*Free access is limited to one course at a time for eligible members.
As a result of this program the learner will:
Successfully diagnose and manage patients with paraproteinemia-associated neuropathy and choose appropriate diagnostic studies to identify paraproteinemia-associated neuropathy, interpret these studies, and apply the results to guide patient care.
- Patient Care
- Medical Knowledge
Date of Release
March 27, 2015
This module is eligible for CME credits for three years from the release date.
Confidentiality of Data
All material © American Academy of Neurology Institute unless otherwise indicated. All rights reserved.
Faculty & Disclosures
Zachary London, MD
University of Michigan
*Dr. London has received personal compensation in an editorial capacity for Medlink Neurology. Dr. London has received royalty payments from the University of Michigan.
A. GORDON SMITH, MD, FAAN
University of Utah Department of Neurology
Salt Lake City, Utah
*Dr. Smith has received personal compensation for activities with Allergan, Baxter Bioscience, Merz, Pfizer and NeurogesX as a consultant..
Tracy King, MA, Associate Director, Education
*Ms. King has nothing to disclose.
Maureen Holtzman, Program Manager, Online Learning
*Ms. Holtzman has nothing to disclose.
Robert Rook, Program Manager, Digital Education Resources
*Mr. Rook has nothing to disclose.
Susan Rodmyre, Senior Director, Education
*Ms. Rodmyre has nothing to disclose.
Kurt Wiersma, Senior Manager, Web Development
*Mr. Wiersma has nothing to disclose.